Articles

There is no consensus about whether atherosclerotic renal artery stenosis should be stented or treated medically. There are strong opinions on both sides and clinical data up to now is heavily...

In recent years, many medical device companies saw the underserved lower extremity as an opportunity to enter the market for peripheral artery disease (PAD) treatments. For this reason, device...

Final five-year results from the ENDEAVOR III trial, comparing the Endeavor Zotarolimus-Eluting Coronary Stent to the Cypher Sirolimus-Eluting Coronary Stent, showed Endeavor had lower long-term...

Editor’s note: Dr. Samady is an associate professor of medicine, division of cardiology,
Emory University School of Medicine, Atlanta. He wrote the following commentary on his...

Fractional flow reserve (FFR) is starting to change cardiologists’ minds about how to treat patients since the release of two-year results from the FAME (FFR vs. Angiography in Multivessel...

In recent years, the U.S. cardiac device market has focused on dynamics in the drug-eluting stent (DES) segment – including events ranging from the 2006 BASKET-LATE trial that caused a tremendous...

Standard drug-eluting stent technology seemed to have taken a backseat at this year’s TCT as cardiologists look forward to the next-generation DES using bioresorbable polymer coatings and totally...

September 29, 2009 – Among the biggest news to come out of TCT 2009 last week was the late-breaking data from the SPIRIT IV trial, which showed Abbott's XIENCE V Everolimus-Eluting Coronary Stent...

When vessels are stretched and ripped via angioplasty balloon expansion, the exposed soft muscle tissue can lead to the proliferation of scar tissue (neointimal hyperplasia) that can reocclude the...

Bare metal stents (BMS) were introduced in 1994 as an improvement over balloon angioplasty alone, which had a high restenosis rate of between 30-40 percent. The cobalt-chromium or stainless steel...